Tiziana Life Sciences Ltd. has announced the upcoming presentation of a scientific poster detailing the design of a Phase 2a double-blind, placebo-controlled clinical trial for nasal foralumab in non-active secondary progressive multiple sclerosis. The presentation will take place at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), scheduled for September 24-26, 2025, in Barcelona, Spain. The poster will outline the trial design and objectives for nasal foralumab, a fully human anti-CD3 monoclonal antibody administered via intranasal delivery. Results from the trial have not yet been presented and will be shared in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-090882), on September 24, 2025, and is solely responsible for the information contained therein.